Skip to main content
logo
Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
6.04
+0.32 (5.59%)
Apr 6, 2026, 4:00 PM EDT - Market closed

Addex Therapeutics Income Statement

Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
0.160.411.621.443.153.88
Revenue Growth (YoY)
-73.24%-74.64%11.92%-54.18%-18.71%36.90%
Gross Profit
0.160.411.621.443.153.88
Selling, General & Admin
1.962.312.673.745.825.75
Research & Development
0.680.851.198.2412.8410.37
Total Operating Expenses
2.643.173.8611.9918.6616.12
Operating Income
-2.48-2.76-2.24-10.54-15.51-12.24
Interest Income
0.020.030.060.030.220.04
Interest Expense
-0-0-0.32-0.29-0.06-0.65
Other Non-Operating Income (Expense)
-3.73-2.18----
Total Non-Operating Income (Expense)
-3.72-2.15-0.26-0.260.15-0.62
Pretax Income
-6.37-4.91-2.5-10.8-15.35-12.86
Net Income
-6.17.06-10.56-20.8-15.35-12.86
Earnings From Discontinued Operations
0.111.97-8.06-10--
Net Income to Common
-6.17.06-10.56-20.8-15.35-12.86
Shares Outstanding (Basic)
111000
Shares Outstanding (Diluted)
111100
Shares Change (YoY)
-9.79%13.18%80.13%141.02%27.88%0.96%
EPS (Basic)
-6.008.40-16.80-55.20-54.00-57.60
EPS (Diluted)
-2.408.40-16.80-55.20-54.00-57.60
Shares Outstanding
1.221.071.040.030.020.01
Free Cash Flow
-1.58-5.37-8.01-16.44-14.74-12.24
Free Cash Flow Per Share
-1.58-3.85-6.49-23.99-51.83-55.05
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1564.90%-671.94%-138.70%-729.49%-491.74%-315.62%
Profit Margin
-3910.00%-1197.28%-154.60%-747.70%-486.85%-331.48%
FCF Margin
-993.65%-1310.80%-495.06%-1137.63%-467.34%-315.52%
EBITDA
-2.45-2.43-1.64-9.9-15.16-11.86
EBITDA Margin
-1545.88%-592.06%-101.58%-685.38%-480.71%-305.85%
EBIT
-2.48-2.76-2.24-10.54-15.51-12.24
EBIT Margin
-1564.90%-671.94%-138.70%-729.49%-491.74%-315.62%
Updated Dec 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q